Research programme: visceral leishmaniasis therapeutics - Advinus Therapeutics/DNDi/Global Alliance for TB Drug Development

Drug Profile

Research programme: visceral leishmaniasis therapeutics - Advinus Therapeutics/DNDi/Global Alliance for TB Drug Development

Alternative Names: DNDI-0690; DNDI-8219; VL-2098

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Global Alliance for TB Drug Development
  • Developer Advinus Therapeutics; Drugs for Neglected Diseases Initiative Foundation
  • Class Nitroimidazoles
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Visceral leishmaniasis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Visceral-leishmaniasis in India (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Visceral-leishmaniasis in Switzerland (PO)
  • 31 Aug 2013 Preclinical development of VL 2098 is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top